CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Abstract

Abstract Introduction: Targeting Bruton tyrosine kinase (BTK) has revolutionized the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Pirtobrutinib, a noncovalent BTK inhibitor, was recently approved for patients who relapsed following covalent BTK inhibitor therapy such as ibrutinib, acalabrutinib, or zanubrutinib. BGB-16673 is an orally available protein degrader that blocks BTK signaling by tagging BTK for degradation through the cell's proteasome pathway, leading to tumor regression. Data from CaDAnCe-101 (BGB-16673-101, NCT05006716), an ongoing phase 1/2 study, demonstrates that BGB-16673 has a to..